STL Volume 19 Number 6
3 POSTS 0 COMMENTSPurchase PDF for $2.79
Update on Drugs and Drug News: November-December 2014
Update on Omalizumab (Xolair®), Pembrolizumab (Keytruda®), Oritavancin (Orbactiv™), and Calcipotriene 0.005% + betamethasone dipropionate 0.064% topical suspension (Taclonex®)
5% Minoxidil: Treatment for Female Pattern Hair Loss
Minoxidil is a Health Canada and US FDA-approved medication for hair loss in men and women. This article review recent Phase III clinical trials on Minoxidil efficacy for the treatment of female patter hair loss.
Chronic Idiopathic Urticaria: Treatment with Omalizumab
Omalizumab has emerged as a very promising treatment option for patients with CSU (Chronic spontaneous urticaria).This editorial reviews mechanisms of action of omalizumab, efficacy, cost and potential side effect profile.